infliximabadalimumabanti-TNFulcerative colitisCrohn’s disease
… anti-TNF (n=37, 26%), p=0.001.In the presence of antibodies to infliximab, 25 (49%) patients immediately changed to an alternative treatm…
6articles mentioning drugs
10drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: anti-TNF ×
anti-TNF
This drug is selected. Its supporting articles are shown below.
Articles mentioning anti-TNF
6 articles · page 1 of 1Anti-IL12/23IL-12/23JAK inhibitorsanti-TNFCrohn’s Disease
…50%). However, 79% required a 3rd line agent, most of which was Anti-IL12/23 (50%). 29% required a 4th line agent and 10% were on a 5th line…
UstekinumabEtanerceptIxekizumabBrodalumabTildrakizumabGuselkumab=21,5 (N=23); IxekizumabRisankizumabAdalimumabGuselkumabSecukinumab
…: p=0,0482; Anti-IL12/23 vs Anti-TNF: p=0,0480; Risankizumab vs Ustekinumab: p=0,0116. No significant differences were found between Risank…
anti-TNFulcerative colitisIBD
…is decreased (1.2, 0.8 and 0.26 years, p=0.008). Early vs later anti-TNF initiation was not associated with surgery-free survival.Conclu…
80.3%
JAK inhibitorIL-12/23anti-IL-12/23anti-TNFulcerative colitisrheumatoid arthritispolymyalgia rheumaticaileocolonic diseaseInflammatory bowel diseaseGRC+3 more
…s switches were anti-TNF to anti-IL-12/23 (n=5) and IL-12/23 to JAK inhibitor (n=4). Non-medication-related actions (e.g. investigations or r…
anti-TNFinflammatory bowel diseaseimmunomodulatorsIBD
…report of EXIT, a randomised controlled trial (RCT) withdrawing anti-TNF in patients with inflammatory bowel disease (IBD), while contin…